The heart failure re-admission rate in the “descending group”, which showed a decrease of 50 pg/mL or more in BNP after 6 months of ARNI administration, was only about 21%, whereas the “rising group”, which showed an increase in BNP of 50 pg/mL or more after 6 months of ARNI administration, was about 50%. The gene discussed is NPPB; the disease is heart failure.